Literature DB >> 23557481

Structural and functional interactions of the prostate cancer suppressor protein NKX3.1 with topoisomerase I.

Liang-Nian Song1, Cai Bowen, Edward P Gelmann.   

Abstract

NKX3.1 (NK3 homeobox 1) is a prostate tumour suppressor protein with a number of activities that are critical for its role in tumour suppression. NKX3.1 mediates the cellular response to DNA damage by interacting with ATM (ataxia telangiectasia mutated) and by activation of topoisomerase I. In the present study we characterized the interaction between NKX3.1 and topoisomerase I. The NKX3.1 homeodomain binds to a region of topoisomerase I spanning the junction between the core and linker domains. Loss of the topoisomerase I N-terminal domain, a region for frequent protein interactions, did not affect binding to NKX3.1 as was shown by the activation of Topo70 (N-terminal truncated topoisomerase I) in vitro. In contrast, NKX3.1 interacts with the enzyme reconstituted from peptide fragments of the core and linker active site domains, but inhibits the DNA-resolving activity of the reconstituted enzyme in vitro. The effect of NKX3.1 on both Topo70 and the reconstituted enzyme was seen in the presence and absence of camptothecin. Neither NKX3.1 nor CPT (camptothecin) had an effect on the interaction of the other with topoisomerase I. Therefore the interactions of NKX3.1 and CPT with the linker domain of topoisomerase I are mutually exclusive. However, in cells the effect of NKX3.1 on topoisomerase binding to DNA sensitized the cells to cellular toxicity and the induction of apoptosis by low doses of CPT. Lastly, topoisomerase I is important for the effect of NKX3.1 on cell survival after DNA damage as topoisomerase knockdown blocked the effect of NKX3.1 on clonogenicity after DNA damage. Therefore NKX3.1 and topoisomerase I interact in vitro and in cells to affect the CPT sensitivity and DNA-repair functions of NKX3.1.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23557481     DOI: 10.1042/BJ20130012

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  8 in total

Review 1.  Controlling gene expression by DNA mechanics: emerging insights and challenges.

Authors:  David Levens; Laura Baranello; Fedor Kouzine
Journal:  Biophys Rev       Date:  2016-11-14

Review 2.  Controlling gene expression by DNA mechanics: emerging insights and challenges.

Authors:  David Levens; Laura Baranello; Fedor Kouzine
Journal:  Biophys Rev       Date:  2016-08-20

3.  CRISPR/Cas9-Mediated Point Mutation in Nkx3.1 Prolongs Protein Half-Life and Reverses Effects Nkx3.1 Allelic Loss.

Authors:  Cai Bowen; Maho Shibata; Hailan Zhang; Sarah K Bergren; Michael M Shen; Edward P Gelmann
Journal:  Cancer Res       Date:  2020-09-17       Impact factor: 12.701

4.  NK3 homeobox 1 (NKX3.1) up-regulates forkhead box O1 expression in hepatocellular carcinoma and thereby suppresses tumor proliferation and invasion.

Authors:  Jingyi Jiang; Zheng Liu; Chao Ge; Cong Chen; Fangyu Zhao; Hong Li; Taoyang Chen; Ming Yao; Jinjun Li
Journal:  J Biol Chem       Date:  2017-09-27       Impact factor: 5.157

5.  Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer.

Authors:  Rajesh Thangapazham; Francisco Saenz; Shilpa Katta; Ahmed A Mohamed; Shyh-Han Tan; Gyorgy Petrovics; Shiv Srivastava; Albert Dobi
Journal:  BMC Cancer       Date:  2014-01-13       Impact factor: 4.430

Review 6.  Oxidative stress in prostate hyperplasia and carcinogenesis.

Authors:  Udensi K Udensi; Paul B Tchounwou
Journal:  J Exp Clin Cancer Res       Date:  2016-09-08

7.  Systems analysis of the prostate tumor suppressor NKX3.1 supports roles in DNA repair and luminal cell differentiation.

Authors:  Chih-Cheng Yang; Alicia Chung; Chia-Yu Ku; Laurence M Brill; Roy Williams; Dieter A Wolf
Journal:  F1000Res       Date:  2014-05-21

8.  Differential Expression Profile of lncRNA in Glioma Cells and the Effect of lncRNA NKX3-1 on Glioma Cells Through Fem1b/SPDEF Pathway.

Authors:  Yang Cai; Ming Wang; Yan Cui; Zhigang Tan; Yugang Jiang
Journal:  Front Oncol       Date:  2021-07-19       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.